

Index

- 1000 Genomes Project, 32
- AAV (adeno-associated virus)
 technology, 73
- ABCA13*, and schizophrenia, 243
- ABCB1* (P-glycoprotein gene),
 variants, and methadone
 dose, 302
- A β (amyloid beta), and Alzheimer's
 disease, 351–353
- absolute risk, 8
- ACE*, and Alzheimer's disease, 376
- acetylation, histones, 79–81, 88
- ACN9*, and alcoholism, 284
- ACTH *see* adrenocorticotrophic
 hormone (ACTH)
- actus reus*, 327
- AD *see* Alzheimer's disease (AD)
- addictions
 testing issues, 331
 vulnerability, 303
see also alcohol dependence;
 alcoholism; drug addiction; nicotine
 dependence
- adeno-associated virus (AAV)
 technology, 73
- adenosine receptor 2A
 (ADORA2A), 95
- adenosine system, genes
 involved in, 95
- ADH*
 and alcoholism, 281, 283–285
 arrangement, 281
- ADH (alcohol dehydrogenases), 280
- ADHD *see* attention-deficit
 hyperactivity disorder
 (ADHD)
- admixture mapping, 19
- adoption studies
 antisocial behavior, 145–146, 156
 gene–environment
 interactions, 152
 antisocial personality disorder,
 148, 317
 attention-deficit hyperactivity
 disorder, 149–150, 168
 and disease etiology, 2–3
 and disorder transmission studies, 3
 genetic epidemiology, 2–3
 major depressive disorder, 215
 mood disorders, 4–5
 post-traumatic stress disorder, 136
- ADORA2A (adenosine
 receptor 2A), 95
- ADRA2A*, and obesity, 276
- ADRB3*, and obesity, 272–273
- adrenocorticotrophic hormone
 (ACTH)
 and opioid addiction, 300
 roles, 300
- affected sibling pair tests, 18
- affective disorders, and schizophrenia,
 233–234
- Affymetrix GeneChip Mapping
 Arrays, 25
- aggression, 145
- agoraphobia (AG)
 classification, 112
 diagnosis, 112
 familial transmission, 113
 genomic studies, 118
 and panic disorder, 118
 prevalence, 90, 112–113
- AGP *see* Autism Genome
 Project (AGP)
- agranulocytosis, antipsychotic-
 induced, 59
- AGRE *see* Autism Genetic Resource
 Exchange (AGRE)
- AKT1*, and schizophrenia, 247
- alcohol, 280
- alcohol dehydrogenases (ADH), 280
- alcohol dependence
 diagnostic criteria, 279
 genetics, 295
 linkage plots, 355
 and nicotine dependence, 294
see also alcoholism
- alcoholism
 candidate genes, 280
 and DNA methylation, 298–299
 endophenotypes, 352
 family studies, 282–283
 follow-up linkage studies, 283–284
 gene–environment interactions, 284
 in treatment, 284
 genetic linkage studies, 282–283
 genetics, 279
 environmental factors, 279–280
 future research, 284–285
 genome-wide association
 studies, 284
 heritability, 5–6
 neurocognitive phenotypes,
 353–359
 and opioid system, 282
 risk factors, 279–280
 twin studies, 279–280
see also alcohol dependence
- alcohol use disorders (AUDs), 279
- aldehyde dehydrogenases
 (ALDH), 280
- ALDH2*, variations, 280–281
- ALDH2*2*, and alcoholism, 280–281,
 284
- ALDH*, and alcoholism, 281, 284–285
- ALDH (aldehyde
 dehydrogenases), 280
- AliBaba2, 40
- alignments, 41–43
 categorization, 42
 global, 42
 local, 42–43
 motif-based, 42
 multiple, 42
 pairwise, 42
 sequence, 31, 41–43
 structural, 43
- alleles, 8–9
- allelic association, concept of, 231
- Allen Brain Atlas, 44
- AlzGene, 37–38
- Alzheimer's disease (AD)
 and amyloid beta, 351–353
 candidate genes, 372, 374
 categorization, 371
 databases, 37–38
 deterministic alleles, 8
 diagnostic criteria, 371
 disease mechanisms, 373–374
 future trends, 378
 gene expression, 377–378
 genetic epidemiology, 371–373
 genetics, 371–378
 genome-wide association studies,
 374–375
 linkage studies, 374

- murine studies, 374
 - prevalence, 371
 - risk loci, 374–378
 - web site resources, 378
 - see also* familial Alzheimer's disease (FAD); late-onset Alzheimer's disease (LOAD)
 - American Civil War, post-traumatic stress disorder, 134
 - amiodarone, drug interactions, 53–54
 - amphetamines
 - attention-deficit hyperactivity disorder studies, 176, 179
 - epigenetic mechanisms, 83–85
 - metabolism, 176
 - amphetamine-type stimulants (ATS), abuse, 306
 - amyloid beta (A β), and Alzheimer's disease, 351–353
 - AN *see* anorexia nervosa (AN)
 - Angelman syndrome, 365–366
 - animal models
 - advantages, 72–73
 - attention-deficit hyperactivity disorder, 173, 176–179
 - pharmacogenetics, 179
 - behavioral assays, 75, 76
 - depression studies, 85
 - drug-addiction studies, 83–85
 - epigenetic mechanisms, 88
 - gene–environment interactions, 178–179
 - gene expression studies, 49
 - genetic susceptibility factor studies, 72–77
 - grooming disorders, 128
 - hemizygous deletions, 178
 - knockdown, 178
 - knockout, 176–177
 - locomotor activity changes, 177
 - noradrenergic pathway, 177
 - obsessive–compulsive disorder, 128
 - post-traumatic stress disorder, 141
 - psychiatric disorders, 73
 - schizophrenia, 73, 76, 251–253
 - selected inbred strains, 178
 - transgenic, 178
- animal phobias, sex differences, 115
- ANK3, and bipolar disorder, 205–206
- ANKK1, and alcoholism, 281–282
- anorexia nervosa (AN)
 - candidate gene association studies, 266–267
 - future research, 267–270
- diagnosis, 262
- diagnostic criteria, 263
- and exercise, 263
- family studies, 264–267
- genetics, 262–270
- heritability, 264
- linkage studies, 265–266
- malnutrition and, 263–264
- and mood disorders, 263
- morbidity, 262
- neurocognitive deficits, 263
- overview, 262
- prevalence, 262
- recovery, 264
- risk factors, 264
- and setshifting, 263
- state–trait characteristics, 263–264
- symptoms, 262
- twin studies, 264–265
- anterior cingulate, roles, 102
- anterior frontal lobes, functions, 192–193
- anterior temporal lobes, functions, 192–193
- anticipation
 - and bipolar disorder, 198
 - and schizophrenia, 230–231
- anticonvulsants, 59–61
- antidepressants
 - adverse reactions, pharmacogenetic studies, 56
 - drug interactions, 53–54
 - genome-wide association studies, 225
 - pharmacodynamics, genetic effects on, 54
 - pharmacogenetics, 53–57, 225
 - pharmacokinetics, genetic effects on, 53–54
 - see also* tricyclic antidepressants (TCAs)
- antipsychotic drugs, 58–59
- antisocial behavior
 - adoption studies, 145, 156
 - and attention-deficit hyperactivity disorder, 145, 149
 - common pathways model, 147
 - comorbidities, 145, 157
 - DSM-IV disorders related to, heritability, 148–150
 - endophenotypes, 154–156
 - environmental factors, 156
 - factors affecting, 156
 - family studies, 145, 153–154
 - future research, 157
 - gene–environment interactions, 145–157
 - adoption studies, 152
 - approaches, 152–153
 - studies, 152–156
 - twin studies, 152
- gene identification, 153–154
- genetics, 145–146
- externalizing factors, 146–148
- and heart rate, 155–156
- heritability, 146
- interventions, 156–157
- measured risk factors, 154–156
- molecular genetic studies, 152
- and psychiatric disorders, 145
- and substance use disorders, 150
- symptoms, 148
- treatment, 157
- twin studies, 145–148, 156
- types of, 145
- use of term, 145
- variance, 147
- antisocial personality disorder, 145
- adoption studies, 148, 317
- family studies, 317
- heritability, 148
- prevalence, 148
- sex differences, 317–318
- symptoms, 148
- twin studies, 317
- anxiety disorders
 - comorbidities, 115–116
 - genetic epidemiology, 5
 - genetic variance, 116
 - and Tourette syndrome, 338
 - see also* generalized anxiety disorder (GAD); obsessive–compulsive disorder (OCD)
- APOE ϵ 2 (apolipoprotein-E ϵ 2) allele, 139–140
- APOE ϵ 4 (apolipoprotein-E ϵ 4) allele, 8
- APOE
 - and Alzheimer's disease, 374
 - and late onset Alzheimer's disease, 373
 - and major depressive disorder, 218–219
- apolipoprotein-E ϵ 2 allele, 139–140
- apolipoprotein-E ϵ 4 allele, 8
- APP, and Alzheimer's disease, 375
- Applied Biosystems
 - SNPplex assays, 25
 - SOLiD, 28, 29
 - TaqMan assays, 25
- arginine vasopressin (AVP), 95
- Ariadne Genomics Pathway Studio, 46
- ArrayExpress, 44
- artificial selection, 324
- ASDs *see* autism spectrum disorders (ASDs)

Index

- association studies
 major depressive disorder, 217–218
 psychostimulant dependence, 308–310
 schizophrenia, 238
 assortative mating, bipolar disorder and, 198
 atomoxetine, attention-deficit hyperactivity disorder studies, 179
 ATP2C2, and language impairment, 164
 ATP6V1B2, and major depression, 221
 ATS (amphetamine-type stimulants), abuse, 306
 attention-deficit hyperactivity disorder (ADHD), 148, 168–179
 adoption studies, 149–150, 168
 animal models, 173, 176–179
 pharmacogenetics, 179
 and antisocial behavior, 145, 149
 and autism, 193
 and bipolar disorder, 208
 brain imaging, 176
 candidate genes, 163, 169–173
 catecholaminergic pathways, 172
 cholinergic pathways, 172
 comorbidities, 126–127, 175
 as complex phenotype, 173–176
 dopaminergic pathways, 169–171
 endophenotypes, neurocognitive, 350–351
 family studies, 168
 gene–environment interactions, 173
 genetic risk factors, 179
 genome-wide association studies, 173
 genome-wide linkage studies, 168–169, 171
 glutaminergic neurotransmission, 172
 heritability, 149–150, 168, 169
 heterogeneity, 173–175
 neurocognitive tests, 175
 neuroimaging studies, 176
 pharmacogenetics, 176
 prevalence, 149, 168
 serotonergic pathways, 172
 structural variants, 173
 symptoms, 149, 168
 and Tourette syndrome, 338
 twin studies, 149–150, 168, 176
 attributable risk, 8
 AUDs *see* alcohol use disorders (AUDs)
 autism, 183–193
 and attention-deficit hyperactivity disorder, 193
 candidate genes, 189–190, 192
 comorbidities, 192
 copy number variations in, 191–192
 diagnostic criteria, 183
 etiology, 183
 biochemical, 192–193
 family studies, 186–187
 genetics, 183
 genetic studies, historical background, 184
 genetic variants, 191–192
 genome-wide association studies, 190–191
 genome-wide linkage studies, 186–187
 heterogeneity, 187
 Ingenuity network analyses, 192
 linkage studies
 historical background, 183–188
 pathways, 192–193
 and Prader–Willi syndrome compared, 365
 sex differences, 188, 191
 twin studies, 183
 Autism Genetic Resource Exchange (AGRE), 186–187
 endophenotype studies, 188
 genome-wide association studies, 190–191
 linkage studies, 187
 Autism Genome Project (AGP)
 genome-wide associations studies, 191
 linkage studies, 187
 studies, 186
 autism spectrum disorders (ASDs), 183–193
 endophenotypes in, 188–189
 and fragile X syndrome compared, 367
 genetics, 183
 loci, 186
 autonomic dysregulation model, 101
 avoidant personality disorder, and social phobia compared, 117
 AVP (arginine vasopressin), 95
 AVPR1A, and autism, 190
 AVPR1B, and panic disorder, 95
 azacitidine, 299

 balanced selection, 202
 BAM (binary SAM), 31
 BDNF, 85–86
 and cocaine administration, 83–84
 and histone acetylation, 87–88
 and suicidal ideation, 56–57
 BDNF *see* brain-derived neurotrophic factor (BDNF)
 behavior
 and environmental factors, 327
 suicidal, 353
 see also antisocial behavior
 behavioral assays, animal models, 75
 behavioral disorders, anticonvulsant therapy, 59
 behavioral endophenotypes, 188
 behavioral genetics
 and criminal responsibility, 327–329
 developments, 324
 ethical issues, 324–334
 and law, ethical issues, 326–329
 and medicine, ethical issues, 326–329
 meta-analyses, 146
 and punishment, 327–329
Bell, Buck v., 325
 benzodiazepines, 59
 panic disorder treatment, 95–96
 binary SAM (BAM), 31
 BIND (Biomolecular Interaction Network Databank), 45
 BIOBASE, 40
 biochemical bases, for autism, 192–193
 BioGPS, 44
 bioinformatics, 44
 BiologicalNetworks, 46
 biomarkers, 49–50
 see also genetic markers
 Biomolecular Interaction Network Databank (BIND), 45
 Biomolecular Object Network Databank (BOND), 45
 BioNetSQL, 46
 BioPAX, 45
 bipolar disorder, 4
 and anticipation, 198
 and assortative mating, 198
 and attention-deficit hyperactivity disorder, 208
 candidate genes, 202–204
 comorbidities, 207–208
 familial transmission, 207
 family epidemiology, 196–199
 family studies, 196
 future research, 208
 gene mapping methods, 199–200
 genetic counseling, 208
 genetics, 209
 genetic susceptibility factors, 69
 genome-wide association studies, 200, 205–206
 linkage studies, 200–202
 lithium treatment, 59–60
 and migraine, 208
 pharmacotherapy, 57

- and schizophrenia, 230–231,
 233–234, 208
 copy number variant differences,
 250–251
 genetic association differences,
 250–251
 subphenotypes, 199
 genetics, 198–199
 mapping genes, 207
 transmission mode, 196–198
 twin studies, 196
- blepharospasm, 127
- BMI *see* body mass index (BMI)
- BMP7, and major depressive
 disorder, 225
- BN *see* bulimia nervosa (BN)
- body mass index (BMI)
 heritability, 272
 variance, 275
- BOND (Biomolecular Object Network
 Databank), 45
- brain
 adolescent, dynamic changes, 75
 gene expression in, research
 issues, 87
 human postmortem, gene
 expression profiling, 49
 structural changes, and panic
 disorder, 103
- brain abnormalities, and panic
 disorder, 102
- brain alterations, gene-induced, 156
- BrainArray, 36
- brain-derived neurotrophic factor
 (BDNF), 56–57
 genes, 140, 201–202
 roles, 85–86, 203–204, 219
- brain dysfunction, and genetic
 susceptibility factors, 77
- brain function, regulatory
 mechanisms, 82
- brain imaging
 attention-deficit hyperactivity
 disorder, 176
 humans, genetic susceptibility factor
 studies, 77
 schizophrenia studies, 234
- brain maturation, postnatal, 75
- brain oscillations
 as endophenotypes, 353–359
- brain responses, to fear, 103–104
- BRD1, and schizophrenia, 247–248
- BRITE, 45
- Buck v. Bell*, 325
- bulimia nervosa (BN)
 diagnosis, 262
 diagnostic criteria, 263
 family studies, 264, 265
 genetics, 262–270
 heritability, 264
 linkage studies, 265–266
 malnutrition and, 263–264
 and mood disorders, 263
 overview, 262
 prevalence, 262
 risk factors, 264
 state–trait characteristics,
 263–264
 symptoms, 262, 263
 twin studies, 264–265
- C2ORF3, and reading disability, 163
- CACNA1C, and bipolar disorder,
 205–206
- CALHMI, and Alzheimer's disease,
 377–378
- candidate gene association
 studies, 28
 anorexia nervosa, 266–269
 post-traumatic stress disorder, 137,
 138
 psychiatric disorders, 49
- candidate genes
 alcoholism, 280
 Alzheimer's disease, 372, 374
 attention-deficit hyperactivity
 disorder, 163, 169–173
 autism, 189–190, 192
 bipolar disorder, 202–204
 cocaine dependence, 309–310
 language impairment, 164–165
 major depressive disorder, 218–219
 obesity, 273, 277
 obsessive–compulsive disorder, 121,
 123–126
 personality disorders, 321
 reading disability, 161–163
 schizophrenia, 204, 231, 238–248
 animal and cell biology studies,
 251–253
 functional polymorphisms and
 mutations, 251
 stimulant dependence, 312
 Tourette syndrome, 341
 types of, 217–218
- candidate gene studies, versus
 genome-wide studies, 18
- cannabinoid receptor 1 gene (CNR1)
see CNR1
- cannabinoid-related genes, and
 stimulant dependence, 312
- carbamazepine (CBZ), 59
 adverse reactions, 60–61
 applications, 60–61
 Stevens–Johnson syndrome
 induction,
 pharmacogenetics, 61
- carbon dioxide hypersensitivity, 96
- catecholaminergic pathways,
 attention-deficit hyperactivity
 disorder, 172
- catechol-O-methyltransferase
 (COMT)
 and antisocial behavior, 154
 and attention-deficit hyperactivity
 disorder, 172
 and bipolar disorder, 204
 localization, 300
 and opioid addiction, 300–301
 panic disorder studies, 94, 105
 polymorphisms, 95
 roles, 94–95, 300
- CBZ *see* carbamazepine (CBZ)
- CCK (cholecystokinin), 95
- CDH17, and major depressive
 disorder, 225
- cdk5, and drug addiction, 83
- cell biology
 in genetic susceptibility factor
 studies, 71–72
 schizophrenia studies, 251–253
- cell cultures, primary, 71
- cellular assays, *in vitro*, 72
- Center for Information Biology
 Gene Expression Database
 (CIBEX), 44
- CFG *see* Convergent Functional
 Genomics (CFG)
- c-fos*
 and drug addiction, 83
 and histone phosphorylation, 81
- Chevron USA, Inc. v. Echazabal*, 334
- childhood apraxia of speech, 160
- children
 conduct disorder, 145
 schizophrenia, 4
- chlorpromazine, 57
- CHNRA5, and stimulant dependence,
 307–308
- CHNRA7, and schizophrenia, 252
- cholecystokinin (CCK), 95
- cholinergic pathways, attention-deficit
 hyperactivity disorder, 172
- CHRH1, and panic disorder, 95
- CHRM2, and alcoholism, 356–357
- CHRNA3
 and lung disease, 292
 and nicotine dependence, 290
- CHRNA4
 in attention-deficit hyperactivity
 disorder, 172
 and lung disease, 292
- CHRNA5
 and alcohol dependence, 294
 and nicotine dependence, 290–292,
 295
- CHRNA7, and schizophrenia, 350

Index

- CHRNA4*, and lung disease, 292
 chromatin
 epigenetic mechanisms, 79–81, 88
 future research, 88
 remodeling, 80, 87
 structure, 84, 87
 cocaine-induced alterations, 84
 chromosomal anomalies, in
 obsessive–compulsive disorder, 130, 130
 chromosomal haplotypes, 16
 chromosomal regions, in
 obsessive–compulsive disorder, 123
 chromosome 1
 1p36, and major depressive disorder, 216
 1p36.3–34.3, and eating disorders, 265
 and alcoholism, 282–283
 and schizophrenia, 238–239, 350–351
 chromosome 2
 2p, and Tourette syndrome, 339
 2q, and autism spectrum disorders, 186, 188
 and alcoholism, 282–283
 and schizophrenia, 239–240
 chromosome 3
 3p12.3, and reading disability, 163
 3q27–28, fine mapping, 122
 and alcoholism, 282–283
 and schizophrenia, 240
 chromosome 4
 4p, and alcoholism, 283
 4q
 and alcoholism, 283
 arrangements, 281
 chromosome 5
 5p15, and autism, 187
 and schizophrenia, 240–241
 chromosome 6
 6p22, and reading disability, 162–163
 6q27, 187
 and schizophrenia, 241–243
 chromosome 7
 7p15.3, and major depressive disorder, 221
 7q31, and language impairment, 164
 7q32, and diabetes, 275
 7q35
 and language impairment, 165
 and Tourette syndrome, 340–341
 7q
 and alcoholism, 284
 and autism, 186, 187
 and alcoholism, 282–283
 and antisocial behavior, 154
 and schizophrenia, 243
 and Tourette syndrome, 340
 chromosome 8, and schizophrenia, 243, 246
 chromosome 9, 9p24, and obsessive–compulsive disorder, 122
 chromosome 10
 10p12, and diabetes, 275
 10q, and alcoholism, 282–283
 chromosome 11
 11p14, and autism, 187
 11p15
 bipolar disorder, 200–201
 and diabetes, 275
 and schizophrenia, 245–246
 chromosome 12
 12p13, and major depressive disorder, 221
 12q24, and diabetes, 275
 chromosome 13
 13q21, and language impairment, 164
 13q31, and schizophrenia, 206–207
 and schizophrenia, 246–247
 chromosome 14, and schizophrenia, 247
 chromosome 15
 15q11–13
 and Angelman syndrome, 365
 and autism spectrum disorder, 192, 365–366
 and obesity, 275
 15q21, and reading disability, 162
 15q25–26, and major depressive disorder, 216, 217
 15q25, and nicotine dependence, 290, 292
 and Prader–Willi syndrome, 365
 chromosome 16
 16p11, and autism spectrum disorder, 184, 185, 192
 16q23–24, and language impairment, 164
 chromosome 17
 17p11.2, and Smith–Magenis syndrome, 366
 17q12, and major depressive disorder, 216
 17q
 and autism, 186
 and depression, 54–55
 and Tourette syndrome, 339
 chromosome 18
 18p11, and bipolar disorder, 207
 18q22, and Tourette syndrome, 340, 341
 and bipolar disorder, 201–202
 chromosome 19, 19q13, and reading disability, 164
 chromosome 20, 20p13, and autism, 187
 chromosome 21, and Down syndrome, 363–364
 chromosome 22
 22q11–13, and autism spectrum disorder, 192
 22q12, and bipolar disorder, 206–207
 and schizophrenia, 247–248
 chromosome 22q deletion syndrome, and obsessive–compulsive disorder, 127–128
 chromosomes, and meiosis, 14–15
 chronic obstructive pulmonary disease (COPD), genetics, 292–294
 chronic social defeat stress, 85–86
 CIBEX (Center for Information Biology Gene Expression Database), 44
 cigarette consumption, and lung cancer, 287
 cigarette smoking
 mortality, 287
 see also nicotine dependence
 cimetidine, drug interactions, 53–54
 citalopram, studies, 55–56
 CJD (Creutzfeldt–Jakob disease), 378
 clinical depression see major depressive disorder (MDD)
CLINT1, and schizophrenia, 240–241
 clozapine, 57–59
 CLSA (Cooperative Linkage Study in Autism), 186–187
CLU, and Alzheimer's disease, 375
 ClustalW, 42
 Cluster-Buster, 36, 40
CMIP, and language impairment, 164
 CNPs see copy number polymorphisms (CNPs)
CNR1
 and post-traumatic stress disorder, 139
 and stimulant dependence, 312
CNTNAP2
 and language impairment, 165, 189, 192–193
 and Tourette syndrome, 340–341
 CNVs see copy number variations (CNVs)
 cocaine
 epigenetic mechanisms, 83–85
 and histone phosphorylation, 82
 cocaine dependence, 306, 314
 candidate genes, 309–310
 genome-wide association studies, 308, 313, 314

Index

- cognitive deficits, in
 schizophrenia, 234
 cohort effect, 198
 color space, 29
 common environment, use of
 term, 114
 common genetic variants, 23
 autism, 191–192
 common pathways model, antisocial
 behavior, 147
 common trait rare gene hypothesis
 (CTRV), 273
 comorbidities, psychiatric disorders, 7
 Complete Genomics, next-generation
 sequencing, 29
 COMPOUND database, 45
 compulsive hoarding, 122
 genetics, 130–131
 computer-based analysis and
 resources, for psychiatric
 genetics research, 34–47
 COMT *see* catechol-O-
 methyltransferase (COMT)
 COMT
 murine studies, 300–301
 and personality disorders, 321
 and schizophrenia, 247–248,
 350–351
 and stimulant dependence, 311
 variants, 128, 300
 conditioning, heritability, 118
 conduct disorder, 148–149
 children, 145
 conscience, development
 failure, 156
 consent issues, genetic information,
 330–331
 controls, selection criteria, 7–8
 Convergent Functional Genomics
 (CFG), 50
 applications, 49
 approaches, 51
 biomarkers, 50
 development, 49
 and genome-wide association
 studies, 49
 p-values and, 51
 Cooperative Linkage Study in Autism
 (CLSA), 186–187
 COPD (chronic obstructive
 pulmonary disease), genetics,
 292–294
 copy number analysis, 26
 copy number polymorphisms (CNPs)
 analysis, 26
 and attention-deficit hyperactivity
 disorder, 173
 copy number variations (CNVs), 4,
 30–31, 375
 in autism, 191–192
 identification, 26, 175
 in obesity, 273
 schizophrenia, 249–250
 and bipolar disorder compared,
 250–251
 in Tourette syndrome, 343
 use of term, 173
 cortico-striato-thalamocortical
 (CSTC) pathways,
 alterations, 127
 corticotropin releasing hormone
 (CRH), 95
 cortisol levels, and suicidal
 behavior, 353
 co-twin control studies, schizophrenia,
 235–237
 CR1, and Alzheimer's disease, 375
 CREB1, and major depressive
 disorder, 215–216
 Creutzfeldt–Jakob disease (CJD), 378
 CRH (corticotropin releasing
 hormone), 95
 CRHR1, major depressive disorder
 studies, 224
 criminal responsibility, and behavioral
 genetics, 327–329
 criminals, sterilization, 325
 CSTC (cortico-striato-
 thalamocortical) pathways,
 alterations, 127
 CTNNA2, and bipolar disorder,
 206–207
 CTRV (common trait rare gene
 hypothesis), 273
 cultural risk factors, migration studies
 and, 3
 CYP1A2, 57–58
 CYP2D6, polymorphisms, 57, 276
 cytochrome p450 system, 53–54
 amphetamine metabolism, 176
 pharmacokinetic studies, 57
 cytogenetic abnormalities
 schizophrenia, 249–250
 Tourette syndrome, 340–341
 Cytoscape, 45–46
 cytosine, methylation, 298
 Danio rerio (zebrafish), as animal
 model, 73
 DAO, and bipolar disorder, 216
 DAOA, and schizophrenia, 204,
 246–247
 Darrow, Clarence, 328
 Darwin, Charles, *On the Origin of*
 Species, 325
 databases
 in linkage studies, 35
 mutations, 36–37, 39
 single nucleotide polymorphisms,
 36–39
 data mining, 40
 DAT (dopamine active transporter)
 gene, 139
 DBH
 and attention-deficit hyperactivity
 disorder, 172
 and post-traumatic stress disorder,
 137–139
 and stimulant dependence, 311–312
 dbSNP (Single Nucleotide
 Polymorphism Database), 39
 DCDC2, and reading disability,
 162–163
 DCTN5, and bipolar disorder, 205
 DCX, and reading disability, 162
 debrisoquin, pharmacokinetics, 53–54
 deletions, schizophrenia, 249–250
 DenNet, D. C., 326–327
 depression
 animal models, 85
 definition, 212
 epigenetic mechanisms, 79–88
 etiology, 212
 neurotrophic model of, 219
 and nicotine dependence, 294
 pharmacotherapy, 53
 symptoms, 85
 and Tourette syndrome, 338
 treatment, 85
 see also major depressive
 disorder (MDD)
 deterministic alleles, 8
 developmental disconnection,
 hypothesis, 193
 developmental disorders
 characteristics, 368
 future research, 369
 genetics, 363–369
 developmental dyspraxia, 160
 DGKH, and bipolar disorder, 206
 diabetes, 275
Diagnostic and Statistical Manual of
 Mental Disorders (DSM)
 DSM-I, traumatic neurosis,
 134–135
 DSM-III
 generalized anxiety disorder, 119
 post-traumatic stress disorder, 134
 social phobia, 112–113
 trauma exposure, 135
 DSM-IV
 alcohol abuse disorders, 279
 alcohol dependence, 279
 anorexia nervosa, 263, 266–267
 antisocial behavior related
 disorders, 148–150
 autism, 183

Index

- Diagnostic and Statistical Manual of Mental Disorders (DSM)* (cont.)
 bulimia nervosa, 263
 nicotine dependence, 288
 panic disorder, 90
 phobias, 112–113
 post-traumatic stress disorder, 134
 trauma exposure, 135
DSM-V, 107
 diathesis–stress model, and
 post-traumatic stress
 disorder, 134
 dietary factors, drug metabolism, 53–54
DISC1, 73
 and schizophrenia, 204, 238–239,
 251
 structure, 70–71
 studies, 69, 72
 animal models, 76–77
 murine, 76
 disease etiology, adoption studies
 and, 2–3
 disease mapping, single nucleotide
 polymorphisms, 23–24
 diseases
 complex, 27
 genetic variants, 35
 genome-wide association studies,
 34–35
 disorder transmission studies,
 adoption studies and, 3
 disrupted in schizophrenia 1 (*DISC1*)
 see DISC1
 dizygotic (DZ) twins, 2, 14
 antisocial behavior studies, 145
 antisocial personality disorder
 studies, 317
 autism studies, 183
 bipolar disorder studies, 196
 carbon dioxide hypersensitivity
 studies, 96
 extraversion studies, 117
 major depressive disorder,
 214–215
 neuroticism studies, 117
 obsessive–compulsive disorder
 studies, 121
 panic disorder studies, 92
 personality disorder studies, 318
 post-traumatic stress disorder
 studies, 136
 schizophrenia studies, 235
 co-twin controls, 235–237
 stimulant dependence studies,
 307–308
 Tourette syndrome studies, 337
 DMS (dystonia myoclonus syndrome),
 and obsessive–compulsive
 disorder, 127
 DNA demethylases, existence of,
 82–83
 DNAm *see* DNA methylation
 (DNAm)
 DNA methods, 23
 DNA methylation (DNAm), 79–82,
 224
 and alcoholism, 298–299
 catalysis, 82–83
 current research, 224
 and gene expression repression, 82
 and opioid addiction, 298–299
 roles, 87
 DNA samples, whole-blood, 23
 DNA sequence variations, 21, 36
 analysis tools, 37
 future research, 46–47
 DNA sequencing
 analysis, 35
 focused, 35
 and genetic studies, 20–21
 tools and resources, 36
 dopamine active transporter (DAT)
 gene, 139
 dopamine beta-hydroxylase (*DBH*)
 gene *see DBH*
 dopamine receptor gene, 137–139
 post-traumatic stress disorder
 studies, 140
 dopamine-related genes, and
 stimulant dependence,
 310–312
 dopaminergic pathways, attention-
 deficit hyperactivity
 disorder, 169–171
 dopaminergic system, 58
 dopamine system
 genes
 in obsessive–compulsive
 disorder, 126
 in post-traumatic stress disorder,
 137–139
 genes involved in, 94–95
 dopamine transporter gene (*SLC6A3*)
 see SLC6A3
 Down syndrome, 363–364
DPYSL2, and schizophrenia, 243
DRD1, polymorphisms, 171
DRD2
 alleles, 154
 and alcoholism, 281–282
 animal models, 178
 polymorphisms, 58, 171, 266–267
 and schizophrenia, 245–246
 and stimulant dependence, 310–311
DRD3
 polymorphisms, 58
 and schizophrenia, 240
 and stimulant dependence, 311
DRD4, 154
 animal models, 178
 and personality disorders, 321
 polymorphisms, 171
 variants, 175
DRD5, polymorphisms, 171
Drosophila melanogaster (fruit fly),
 as animal model, 73
 drug addiction
 epigenetic mechanisms, 79–88
 treatment, 83
 see also cocaine dependence, heroin
 addiction; opioid addiction;
 psychostimulant dependence;
 stimulant dependence
 drug-addiction studies, animal
 models, 83–85
 DRUG database, 45
 drug interactions, antidepressants,
 53–54
 drug metabolism, dietary factors,
 53–54
 drug relapse, mechanisms, 83
 drug responses, environmental factors,
 61–65
DSM see *Diagnostic and Statistical
 Manual of Mental Disorders
 (DSM)*
DTNBP1, and schizophrenia, 241–243
 duplications, schizophrenia, 249–250
Durham v. US, 327–328
 dynamic programming algorithms, 42
 dyslexia *see* specific reading disability
 (SRD)
 dystonia myoclonus syndrome (DMS),
 and obsessive–compulsive
 disorder, 127
 DYX loci, 161
DYX1, 162
DYX1C1, and reading disability, 162
DYX2, 162–163, 165–166
DYX5, 163
DYX8, 165–166
EAAC1 see SLC1A1
 eating disorders (EDs)
 linkage studies, 265–266
 morbidity, 262
 prevalence, 262
 symptoms, 263
 see also anorexia nervosa (AN);
 bulimia nervosa (BN); obesity
 EBI *see* European Bioinformatics
 Institute (EBI)
 EBI Dali, 43
*Echazabal, Chevron U.S.A.,
 Inc. v.*, 334
egr-1, and cocaine withdrawal,
 83–84

- electroencephalography (EEG)
 interhemispheric theta coherence, 356–357
 resting, beta power, 354–356
 Elston–Stewart algorithm, 26–27
 EMBOSS, 42–43
 E-MSD (Macromolecular Structure Database), 43
 EN2, and autism, 189–190
 ENCODE Project, 20, 32, 47
 regions, 40–41
 endophenotypes
 alcoholism, 352
 for antisocial behavior, 154–156
 attention-deficit hyperactivity disorder, 350–351
 in autism spectrum disorders, 188–189
 behavioral, 188
 brain oscillations as, 353–359
 concept of, 348
 conceptual development, 347–348
 definition, 187–188
 family studies, 349
 heritability, 348–349
 late onset Alzheimer's disease, 375–377
 neurochemical metabolites as, 351–353
 neuroimaging, 351
 obsessive–compulsive disorder, 188
 for psychiatric disorder
 classification, 9
 psychiatric disorders and, 349
 in psychiatric genetics, 347–360
 applications, 349–359
 future trends, 359–360
 identification criteria, 348–349
 schizophrenia, 350–351
 state independence, 349
 variations, 349
 ENU (*N*-ethyl-*N*-nitrosourea)
 mutants, 178
 environmental factors
 alcoholism, 279–280
 antisocial behavior, 156
 and behavior, 327
 drug responses, 61–65
 identification, 9
 in obsessive–compulsive disorder, 130
 Tourette syndrome, 342
see also gene–environment interactions ($G \times E$)
 environmental risk factors, migration studies and, 3
 environmental variance, phobias, twin studies, 114
EPHB1, and major depressive disorder, 225
 EPIC (Events Preceding Interstitial Cystitis), 99–100
 epidemiology
 phobias, 112–113
see also genetic epidemiology
 epigenetic mechanisms, 79–83
 animal models, 88
 in depression, 79–88
 in drug addiction, 79–88
 future research, 88
 and gene expression, 79
 epigenetic modifications, 51
 obesity, 275–276
 epigenetics
 definition, 79
 field of study, 79
 future research, 88
 major depressive disorder, 223–224
 future research, 226
 mu-opioid receptor, 298–299
 personality, 322
 post-traumatic stress disorder, 140–141
 research issues, in psychiatry, 87
 schizophrenia, 231–232
 Tourette syndrome, 343–344
EPSIN4, and schizophrenia, 240–241
 eQTL *see* expression quantitative trait locus (eQTL)
 EROs (even-related oscillations), theta and delta, 357–359
 escitalopram, studies, 55–56
 ethanol, consumption, 280
 ethical issues
 behavioral genetics, 324–334
 eugenics, 324–326
 sterilization, 325
N-ethyl-*N*-nitrosourea (ENU)
 mutants, 178
 eugenics, 324–326
 European Bioinformatics Institute (EBI)
 GeneWise, 35
 InterProScan, 43
 Macromolecular Structure Database, 43
 even-related oscillations (EROs), theta and delta, 357–359
 Events Preceding Interstitial Cystitis (EPIC), 99–100
 exercise, and anorexia nervosa, 263
 expanded spectrum approach, 97–102
 ExPasy Translate, 35
 expression quantitative trait locus (eQTL)
 autism studies, 188–189
 resources, 44
 externalizing disorders
 heritability, 146–148
 twin studies, 116–117
 use of term, 145
 extraversion, 117
 eye-tracking dysfunction, and schizophrenia, 350
FAAH, and stimulant dependence, 312
 FACS (fluorescence activated cell sorting), 87
 factor analysis, personality disorders, 320
 Fagerström Test of Nicotine Dependence (FTND), 288
 familial aggregation, 3
 indicators, 1–2
 familial Alzheimer's disease (FAD), 376
 diagnostic criteria, 371
 genetic susceptibility factors, 371
 familial recurrence, schizophrenia, 232–233
 familial specificity, phobias, 114
 familial transmission
 bipolar disorder, 207
 phobias, 113
 schizophrenia, 207
 family epidemiology, bipolar disorder, 196–199
 family history screen (FHS), 96–97
 Family Interview for Genetic Studies (FIGS), 96–97
 family studies
 advantages, 2
 alcoholism, 282–283
 anorexia nervosa, 264
 antisocial behavior, 145, 153–154
 antisocial personality disorder, 317
 attention-deficit hyperactivity disorder, 168
 autism, 186–187
 bipolar disorder, 196
 bulimia nervosa, 264
 early, 34
 endophenotypes, 349
 generalized anxiety disorder, 119
 genetic epidemiology, 1–2
 major depressive disorder, 213–214
 obsessive–compulsive disorder, 121, 123
 panic disorder, 90–92
 post-traumatic stress disorder, 135–136
 psychiatric disorders, 69
 sampling, 7

Index

- family studies (cont.)
 schizophrenia
 cognitive deficits and imaging changes, 234
 segregation analysis, 237–238
 subtypes, 232–233
 variance component analysis, 237–238
 single nucleotide polymorphism genotyping, 26–27
 social phobia traits, 117–118
 stimulant dependence, 306–307
 substance use disorders, 5, 6
 Tourette syndrome, 337
- FASTA, 42
 fastq, 31
 fear
 brain responses to, 103–104
 conditioning, susceptibility to, 118
 irrational, 113
 and post-traumatic stress disorder, 103–104
 prevalence, 113
 processing, in panic disorder, 107
 stimuli, masked versus unmasked, 104
 unconditioned, 102–103
- fearful faces, amygdala activation, 106
- FHS (family history screen), 96–97
- FIGS (Family Interview for Genetic Studies), 96–97
- FKBP5*
 and major depressive disorder, 219
 and post-traumatic stress disorder, 139–140
- fluorescence activated cell sorting (FACS), 87
- fluoxetine, 86, 179, 224
 pharmacokinetics, 53–54
- FMRI*, and fragile X syndrome, 366–367
- fMRI (functional magnetic resonance imaging), 351
- focal dystonias, 127
- FosB, and drug addiction, 83
- FOXP2*, and language impairment, 164
- fragile X mental retardation protein (FMRP), 366–367
- fragile X syndrome (FXS)
 and autism spectrum disorders compared, 367
 etiology, 366–367
 future research, 368–369
 genetics, 366–369
 and mGluR theory, 367–368
 prevalence, 367
 sex differences, 367
- fruit flies, 73
- FTND (Fagerström Test of Nicotine Dependence), 288
- functional analysis, computer-based, 35
- functional assessment, genes, 38
- functional imaging studies
 limitations, 103
 panic disorder, 102–104, 107
- functional magnetic resonance imaging (fMRI), 351
- functional polymorphisms, schizophrenia, 251
- functional validation, of genetic susceptibility factors, for psychiatric disorders, 69–77
- FXS *see* fragile X syndrome (FXS)
- FXD6*, and schizophrenia, 245–246
- FZD3*, and schizophrenia, 243
- GABA-ergic system, genes involved in, 95–96
- GABA system *see* gamma-aminobutyric acid (GABA) system
- GABHS (group A *beta* hemolytic streptococci), 342
- GABRA1*, and schizophrenia, 240–241
- GABRA2*, and alcoholism, 282–283, 354–357
- GABRA4*, and alcoholism, 354–356
- GABRA6*, and schizophrenia, 240–241
- GABRB1*, and alcoholism, 354–356
- GABRB2*, and schizophrenia, 240–241
- GABRG1*, and alcoholism, 283, 354–356
- GABRP*, and schizophrenia, 240–241
- GAD2*, and obesity, 275
- GAD* *see* generalized anxiety disorder (GAD)
- GAD* (glutamic acid decarboxylase), 95–96
- Galton, Sir Francis, 324–325
- gamma-aminobutyric acid (GABA) system
 panic disorder studies, 95–96
 receptor genes, and alcoholism, 283
- GENDEP (Genome-Based Therapeutic Drugs for Depression), 55–56
- gender differences *see* sex differences
- gene association studies, hypothesis-driven, opioid addiction, 302
- GENE database, 45
- gene dosage, disorders, 363–364
- gene–environment correlations, 6
- gene–environment interactions
 ($G \times E$), 6, 151–152
 alcoholism, 284
- animal models, 178–179
- antisocial behavior, 145–157
 adoption studies, 152
 approaches, 152–153
 studies, 152–156
 twin studies, 152
- attention-deficit hyperactivity disorder, 173
- definition, 151–152
- major depressive disorder, 224
- obesity, 272–273
- and post-traumatic stress disorder, 142
- substance use disorders, 150
- gene expression, 44
- Alzheimer's disease, 377–378
- in brain, research issues, 87
- databases, 44
- drug-induced, 83
- epigenetic mechanisms and, 79
- major depressive disorder, 222–223
- future research, 226
- repression, 82
- Gene Expression Omnibus (GEO), 44
- gene expression profiling, 50
- gene expression studies
 animal models, 49
 developments, 51
 future trends, 51
 human postmortem brain, 49
 large-scale, viability, 49
 in psychiatric disorders, 49–51
 p-values in, 50–51
- GeneGo MetaCore, 46
- GeneHunter program, 26–27
- gene identification
 antisocial behavior, 153–154
 future trends, 49
 genetic epidemiology and, 7–10
- gene localizations, in reading disability, 161
- gene mapping, major depressive disorder, 215–222
- gene mapping methods
 bipolar disorder, 199–200
 subphenotypes, 207
- Gene Ontology (GO) database, 45
- generalized anxiety disorder (GAD), 119–120
 comorbidities, 117
 genetic epidemiology, 5
 genetics, 112–120
- generalized social phobia, 117
- genes
 additive
 generalized anxiety disorder, 120
 and phobias, 114–115, 117

- in adenosine system, 95
 - in dopamine system, 94–95
 - functional assessment, 38
 - in GABA-ergic system, 95–96
 - in G-protein signaling regulators, 96
 - in neuropeptide systems, 95
 - in obsessive-compulsive disorder, 121, 123–126
 - rare, in obsessive-compulsive disorder, 130, 130
 - related to carbon dioxide hypersensitivity, 96
 - in serotonin system, 93–94
 - see also* candidate genes
 - GENESEQ, 45
 - gene set expression analysis (GSEA), 44
 - genes-to-brain-to-antisocial-behavior model, 156
 - genetic analysis, issues, 19–20
 - genetic association
 - bipolar disorder, 200
 - schizophrenia and bipolar disorder compared, 250–251
 - genetic bases, of psychiatric disorders, methods, 23
 - genetic case-control association
 - studies, post-traumatic stress disorder, 137–140
 - genetic counseling, bipolar disorder, 208
 - genetic engineering, murine, 73
 - genetic epidemiology, 1–3
 - adoption studies, 2–3
 - Alzheimer's disease, 371–373
 - applications, to gene identification, 7–10
 - early studies, 1
 - family studies, 1–2
 - field of study, 1
 - migration studies, 3
 - panic disorder, 90
 - phobias, 113–118
 - future research, 119
 - of psychiatric disorders, 1–10
 - risk estimation, 8
 - schizophrenia, 3–4
 - twin studies, 2
 - genetic factors, interactions, 20
 - genetic heterogeneity, 6, 20
 - genetic imprinting, 365–366
 - genetic information
 - applications, social, 324–326
 - consent issues, 330–331
 - control of, 329
 - forensic, privacy issues, 329–330
 - health professionals and, 332–333
 - privacy of, 329
 - genetic linkage
 - alcoholism, 282–283
 - bipolar disorder, 200
 - schizophrenia, 238
 - genetic markers, 34–35
 - see also* biomarkers
 - genetic risk factors *see* genetic susceptibility factors
 - genetics
 - alcohol dependence, 295
 - alcoholism, 279
 - alcohol use disorders, 279
 - Alzheimer's disease, 371–378
 - Angelman syndrome, 365–366
 - anorexia nervosa, 262–270
 - antisocial behavior, 145
 - autism, 183
 - autism spectrum disorders, 183
 - bipolar disorder, 209
 - subphenotypes, 198–199
 - bulimia nervosa, 262–270
 - chronic obstructive pulmonary disease, 292–294
 - compulsive hoarding, 130–131
 - developmental disorders, 363–369
 - Down syndrome, 363–364
 - fragile X syndrome, 366–369
 - generalized anxiety disorder, 112–120
 - grooming disorders, 128–130
 - heroin addiction, 301, 302–303
 - historical background, 324
 - lung cancer, 292–295
 - lung disease, 292–295
 - major depressive disorder, 212–227
 - Mendelian, 324
 - nicotine dependence, 288
 - and psychiatric disorders, 294–295
 - obesity, 272–277
 - obsessive-compulsive disorder, 121–131
 - future research, 130–131
 - opioid addiction, 297–303
 - origin of term, 347
 - personality disorders, 316–322
 - phobias, 112–120
 - Prader-Willi syndrome, 365–366
 - psychostimulant dependence, 308–310
 - reading disability, 161
 - and responsibility, 326–329
 - Rett's disorder, 364–365
 - schizophrenia, 230–253
 - Smith-Magenis syndrome, 366
 - speech sound disorder, 165–166
 - stimulant dependence, 306–314
 - Tourette syndrome, 126–127, 336–344
 - weight loss, 276
 - see also* behavioral genetics;
 - epigenetics; pharmacogenetics; psychiatric genetics
 - genetic studies
 - autism, historical background, 184
 - DNA sequencing and, 20–21
 - limitations, 61–65
 - panic disorder, 90
 - issues, 107
 - limitations, 106
 - post-traumatic stress disorder, 135–140
 - see also* molecular genetic studies
 - genetic susceptibility factors
 - animal models, 72–77
 - assays, 74–75
 - DISC1 studies, 76–77
 - readouts relevant to psychiatric disorders, 74–75
 - biochemical studies, 69
 - bipolar disorder, 69
 - and brain dysfunction, 77
 - cell biology studies, 71–72
 - during neurodevelopment, 75
 - familial Alzheimer's disease, 371
 - for-profit testing, 331–332
 - human studies, with brain imaging, 77
 - late onset Alzheimer's disease, 373
 - pathways, 70–71
 - protein chemistry studies, 69–71
 - for psychiatric disorders, functional validation, 69–77
 - schizophrenia, 4, 69
- genetic variance
 - anxiety disorders, 116
 - phobias, twin studies, 114
- genetic variants
 - autism, issues, 191
 - diseases, 35
 - functional assessment, 38
 - germ-line, 23
 - identification, 61–65
 - linkage and linkage disequilibrium, 14–17
 - multiple comparisons, 19–20
 - types of, 23
 - see also* common genetic variants; copy number polymorphisms (CNPs); copy number variations (CNVs); rare genetic variants
- gene transfer, *in utero*, 73–74, 76–77
- GeneWise, 35
- GenMAPP, 46
- Genome-Based Therapeutic Drugs for Depression (GENDEP), 55–56
- genome scan meta-analysis (GSMA), 202
- genome sequencing, complete, 35

Index

- genome-wide association studies (GWAS), 19–20, 55–56
 alcoholism, 284
 Alzheimer's disease, 374–375
 antidepressants, 225
 applications, 27
 disease studies, 34–35
 attention-deficit hyperactivity disorder, 173
 autism, 190–191
 bipolar disorder, 200, 205–206
 case-control, 27
 cocaine dependence, 308, 314
 and Convergent Functional Genomics, 49
 development, 24–25
 errors, sources of, 28
 late onset Alzheimer's disease, 374–375
 limitations, 35, 49
 major depressive disorder, 219–222
 nicotine dependence, 289–292, 295
 obesity, 274
 obsessive-compulsive disorder, 122–123, 130
 opioid addiction, 302–303
 panic disorder, 93, 106
 permutational analysis, 28
 personality disorders, 321–322
 post-traumatic stress disorder, 141–142
 single nucleotide polymorphism genotyping, 27–28
 stimulant dependence, 312–313
 Tourette syndrome, 342–343
 use of term, 23
 genome-wide linkage studies
 attention-deficit hyperactivity disorder, 168–169, 171
 autism, 186–187
 genome-wide studies, versus candidate gene studies, 18
 genomic imprinting disorders, 365
 genomics
 future research, 47
 impacts, on psychiatric science and practice, 9–10
 see also Convergent Functional Genomics (CFG)
 genomic studies, phobias, 118–119
 genotype likelihood format (GLF), 31
 genotyping
 concept of, 347
 future research, 46–47
 GEO (Gene Expression Omnibus), 44
 Gibbs sampling, 42
 GLF (genotype likelihood format), 31
 global alignments, 42
 glucocorticoid receptor (GR), polymorphisms, 139
 glutamate system genes, 123
 glutamic acid decarboxylase (GAD), 95–96
 glutaminergic neurotransmission, in attention-deficit hyperactivity disorder, 172
 P-glycoprotein gene (*ABCB1*), variants, and methadone dose, 302
 GNB3, and major depressive disorder, 218–219
 GO (Gene Ontology) database, 45
 GPR158, and obesity, 275
 GPRIN2, and obesity, 273
 G-protein signaling regulators, genes involved in, 96
 GR (glucocorticoid receptor), polymorphisms, 139
 GRIN1, and weight loss, 276
 GRK3, and bipolar disorder, 204
 GRM3, and schizophrenia, 243, 253
 GRM7
 and attention-deficit hyperactivity disorder, 176
 and major depressive disorder, 221–222
 GRM8, and alcoholism, 357–359
 GRN, and Alzheimer's disease, 378
 grooming disorders, 128–130
 group A *beta* hemolytic streptococci (GABHS), 342
 GSEA (gene set expression analysis), 44
 GSMA (genome scan meta-analysis), 202
 GWAS see genome-wide association studies (GWAS)
 G × E see gene-environment interactions (G × E)
 haloperidol, 57, 224, 252
 haplotype blocks, 39
 haplotypes, chromosomal, 16
 HapMap Project see International HapMap Project
 Haseman-Elston linkage algorithm, 118–119
 HATs (histone acetyltransferases), 81
 HD see Huntington's disease (HD)
 HDACs see histone deacetylases (HDACs)
 HDC, and Tourette syndrome, 336–339
 HDMs (histone demethylases), 82
 health professionals, and genetic information, 332–333
 heart rate, and antisocial behavior, 155–156
 hemizygous deletions, animal models, 178
 HEP (Human Epigenome Project), 47
 heritability
 alcoholism, 5–6
 anorexia nervosa, 264
 antisocial behavior, 146
 antisocial personality disorder, 148
 attention-deficit hyperactivity disorder, 149–150, 168–169
 body mass index, 272
 bulimia nervosa, 264
 conditioning, 118
 conduct disorder, 148–149
 of DSM-IV disorders related to antisocial behavior, 148–150
 endophenotypes, 348–349
 establishment, 13
 estimates, 3
 externalizing disorders, 146–148
 migration studies, 14
 missing, 274–275
 mood disorders, 196
 nicotine dependence, 289
 obesity, 272
 oppositional defiant disorder, 149
 panic disorder, 92
 personality disorders, 318–321
 personality traits, 326
 phobias, sex differences, 114
 psychopathic traits, 150–151
 schizophrenia, 230–231
 smoking initiation, 288
 stimulant dependence, 306–308
 substance use disorders, 150
 Tourette syndrome, 337
 traits, 113
 twin studies, 14
 heritability estimates, psychiatric disorders, 3
 heroin addiction, genetics, 301–303
 heterogeneity
 autism, 187
 phenotypic, 20
 see also genetic heterogeneity
 HGMD (Human Gene Mutation Database), 37–38
 HGVBase, 37–38
 high-density single nucleotide polymorphism (SNP) genotyping
 arrays, 23
 technologies, 24–25
 high-throughput assays, 44
 L-histidine decarboxylase (HDC) see HDC
 histone acetyltransferases (HATs), 81

- histone deacetylases (HDACs), 81
 cocaine and, 84
 inhibitors, 86
- histone demethylases (HDMs), 82
- histone methyltransferases (HMTs), 82
 inhibition, 85
- histones
 acetylation, 79–81, 88
 and *bdnf*, 87–88
 genome-wide studies, 81
 and epigenetic mechanisms, 79–81
 methylation, 79–82, 88
 localization, 82
 regulatory mechanisms, 82
 phosphorylation, 79–82, 85
 localization, 81
 regulatory mechanisms, 82
- HLA, and schizophrenia, 241–243
- HLA-B*1502 allele test, 65
- HMTs *see* histone methyltransferases (HMTs)
- hoarding *see* compulsive hoarding
- Holmes, Oliver Wendell, 325
- HPA axis *see* hypothalamic-pituitary-adrenal (HPA) axis
- 5-HT1A receptor, 93–94
- 5-HT1B (5-hydroxytryptamine-1B receptor), and opioid addiction, 301
- 5-HT2A receptors
 and major depressive disorder, 55
 and obesity, 276
 polymorphisms, 58, 94
- 5-HT2C receptors, 58–59
- 5-HT (hydroxytryptamine), 154
- HTR1B, 301
- HTR1D, and eating disorders, 265
- HTR2A
 anorexia nervosa studies, 267–269
 and attention-deficit hyperactivity disorder, 172
 and major depressive disorder, 55–56
- htt* (*huntingtin*), and Huntington's disease, 69
- 5-HTTLPR *see* serotonin-transporter-linked polymorphic region (5-HTTLPR)
- Human Epigenome Project (HEP), 47
- Human Gene Mutation Database (HGMD), 37–38
- human genetics research
 analysis strategies, overview, 13–21
 developments, 13
 field of study, 13
 future trends, 21
- human genome
 properties, 13
 sequencing, 347
 variant identification, 13
 strategies, 34
- Human Genome Project, 324
- human studies, genetic susceptibility factors, with brain imaging, 77
- huntingtin* (*htt*), and Huntington's disease, 69
- Huntington's disease (HD),
 etiology, 69
- hybridization-based target enrichment, 32
- 6-hydroxydopamine (6-OHDA), 177
- 5-hydroxytryptamine-1B receptor (5-HT1B), and opioid addiction, 301
- hydroxytryptamine (5-HT), 154
- hypercapnia, 96
- hypothalamic-pituitary-adrenal (HPA) axis, 224
 and major depressive disorder, 219
- IC *see* interstitial cystitis (IC)
- ICD-10 (*International Classification of Diseases*), alcohol abuse disorders, 279
- idiopathic generalized epilepsy (IGE), and schizophrenia, 249–250
- IGE (idiopathic generalized epilepsy), and schizophrenia, 249–250
- IGF2, and obesity, 276
- IL15, and obesity, 273
- IL28RA, and suicidal ideation, 56–57
- Illumina
 BeadArray Mapping arrays, 25
 Genome Analyzer, 28, 29
 HiSeq, 29
 procedures, 25
- imaging changes, in
 schizophrenia, 234
- imaging genetics, 104–106
- IMGSAC *see* International Molecular Genetic Study of Autism Consortium (IMGSAC)
- imipramine, 224–225
 pharmacokinetics, 53–54
- IMMP2L, and Tourette syndrome, 340
- inbred strains, selected, 178
- incomplete penetrance, 6
- induced pluripotent stem (iPS) cells, 71
- infections
 and immune response, Tourette syndrome, 342
 streptococcal, 130
 viral vectors, 71
- Ingenuity network analyses,
 autism, 192
- Ingenuity Pathway Analysis, 46
- inheritance
 general personality dimensions, 320–321
 Mendelian laws of, 1–2
 modes of, 6
 personality disorders, 318–320
- interhemispheric theta coherence, 356–357
- interleukin receptors, encoding, 56–57
- internalizing disorders, twin studies, 116–117
- International Classification of Diseases (ICD-10)*, alcohol abuse disorders, 279
- International HapMap Project, 18, 24–25
 databases, 39
- International Molecular Genetic Study of Autism Consortium (IMGSAC), 183–186
 two-stage genome scan, 186
- International Schizophrenia Consortium, 46–47
- InterProScan, 43
- interstitial cystitis (IC), 99
 case-control studies, 98, 99–100
- in utero* gene transfer, 73–74, 76–77
- inversions, 30–31
- in vitro* cellular assays, 72
- iPS cells *see* induced pluripotent stem (iPS) cells
- irrational fears, and phobias, 113–115
- JAligner (software), 42
- kappa-opioid receptor (KOPr), 299
- KE family, 164
- KIAA0319, and reading disability, 162–163, 166
- knockdown animal models, 178
- knock-in mice, 73
- knockout animal models, 176–177
- knockout mice, 73, 176–177
- KOPr *see* kappa-opioid receptor (KOPr)
- Kyoto Encyclopedia of Genes and Genomes (KEGG), 45–46
- lactate dehydrogenase (LDH), 96
- Lander–Green algorithm, 26–27
- language impairment (LI), 164–165
 deficits, 166
 future research, 166
 see also specific language impairment (SLI)

Index

- large deletions, 30–31
 large insertions, 30–31
 late onset Alzheimer's disease (LOAD)
 diagnostic criteria, 371
 endophenotypes, 375–377
 genetic susceptibility factors, 373
 genome-wide association studies, 374–375
 law, and behavioral genetics, ethical issues, 326–329
 LD *see* linkage disequilibrium (LD)
 LDH (lactate dehydrogenase), 96
 learning disabilities, 160–166
 definitions, 160–161
 diagnostic issues, 160–161
 prevalence, 160–161
 leptin gene, 58–59
 LI *see* language impairment (LI)
 linkage analysis, 17
 Tourette syndrome, 338–339
 linkage disequilibrium (LD), 200, 309
 biological significance, 20
 concept of, 27, 231
 functional assessments, 20
 genetic variants, 14–17
 mapping, 17–18
 single nucleotide polymorphisms, 24
 and variant segregation in populations, 15–17
 linkages
 biological information, leveraging strategies, 35
 biological significance, 20
 functional assessments, 20
 genetic variants, 14–17
 mapping, 17–18
 special designs, 18–19
 and recombination, 14–15
 linkage studies, 26–27
 Alzheimer's disease, 374
 analysis, 26–27
 anorexia nervosa, 265–266
 autism
 historical background, 183–188
 overview, 187–188
 bipolar disorder, 200–202
 bulimia nervosa, 265–266
 databases in, 35
 early, 34
 eating disorders, 265–266
 follow-up, alcoholism, 283–284
 major depressive disorder, 215–216
 obesity, 274
 obsessive-compulsive disorder, 122
 panic disorder, 92, 99
 psychostimulant dependence, 308
 schizophrenia, 231
 single nucleotide polymorphism genotyping, 26–27
 surrogate markers, 26
 linkage variables, identification, 188–189
 lithium, 59–60
 LOAD *see* late onset Alzheimer's disease (LOAD)
 local alignments, 42–43
 loci, linkages, 14–15
 locomotor activity changes, animal models, 177
 logarithm of odds (LOD) scores, 18, 24, 26–27, 122, 231
 lung cancer
 and cigarette consumption, 287
 genetics, 292–295
 prevalence, 287
 lung disease, genetics, 292–295
 lymphocyte protein studies, 50
 lyonization, 79–81
 Macromolecular Structure Database (E-MSD), 43
 major depressive disorder (MDD), 4
 adoption studies, 215
 association studies, 217–218
 candidate genes, 218–219
 citalopram studies, 55
 diagnosis, 227
 diagnostic criteria, 212
 epigenetics, 223–224
 future research, 226
 etiology, 212
 family studies, 213–214
 future research, 225–227
 gene-environment interactions, 224
 gene expression, 222–223
 future research, 226
 gene function, 222–223
 future research, 226
 murine models, 222–223
 gene mapping, 215–222
 genetic epidemiology, 212–215
 genetics, 212–227
 genome-wide association studies, 219–222
 linkage studies, 215–216
 pathophysiology, 227
 pharmacogenetics, 53, 225
 future trends, 227
 pharmacokinetics, 54
 phenotypes
 alternative, 216–217
 definition, 212
 future research, 227
 sex differences, 215–216
 twin studies, 214–215, 224
 malnutrition, 263–264
 MANEA, and stimulant dependence, 313
 manic-depression *see* bipolar disorder
 MAOA *see* monoamine oxidase A (MAOA)
 MAPT, and Alzheimer's disease, 373–374, 376–378
 MAST, 40
 MATCH, 40
 mate-pair sequencing, 29
 mating, non-random, 7
 Maudsley Twin Register, 121
 MC2R *see* melanocortin receptor type 2 (MC2R)
 MDD *see* major depressive disorder (MDD)
 measured risk factors, 154–156
 MECP2, and Rett's disorder, 364–365
 medicine, and behavioral genetics, ethical issues, 326–329
 MedScan, 46
 meiosis, chromosomes and, 14–15
 melanocortin receptor type 2 (MC2R) and opioid addiction, 299–300
 roles, 299–300
 MEME, 40
 Mendel, Gregor Johann, 112
 Mendelian genetics, 324
 Mendelian laws, of inheritance, 1–2
 Mendelian ratio, 2
 mens rea, 327
 mental disorders *see* psychiatric disorders
 mental illnesses *see* psychiatric disorders
 MERLIN program, 26–27, 122
 MET, and autism, 189–190, 192–193
 methamphetamine dependence, 314
 genome-wide association studies, 313
 methadone, opioid addiction treatment, 302
 methylation
 cytosine, 298
 histones, 79–82, 88
 see also DNA methylation (DNAm)
 methylphenidate, attention-deficit hyperactivity disorder studies, 176, 179
 methylthioninium chloride (MTC), 374
 mGluR theory, and fragile X syndrome, 367–368
 mice
 in animal models, 72–73
 COMT studies, 300–301

- DISC1* studies, 76, 251
 knock-in, 73
 knockout, 73, 176–177
 major depressive disorder studies, 222–223
 over-grooming behavior, 128–130
 schizophrenia studies, 251–253
 transgenic, 73
 microarray platforms, 49
 microarray studies, Tourette syndrome, 342–343
 migraine, and bipolar disorder, 208
 migration studies
 genetic epidemiology, 3
 heritability, 14
 missing heritability, 274–275
 mitral valve prolapse (MVP), 101
 MoD Tools, 40
 molecular genetic studies
 antisocial behavior, 152
 panic disorder, 92–97
 molecular manipulations, 71, 73–74
 molecular profiling, 75
 monoamine oxidase A (MAOA)
 antisocial behavior studies, 152–154
 attention-deficit hyperactivity disorder studies, 172
 panic disorder studies, 94
 monozygotic (MZ) twins, 2, 14
 antisocial behavior studies, 145
 antisocial personality disorder studies, 317
 attention-deficit hyperactivity disorder studies, 176
 autism studies, 183
 bipolar disorder studies, 196
 carbon dioxide hypersensitivity studies, 96
 extraversion studies, 117
 major depressive disorder, 214–215
 neuroticism studies, 117
 obesity studies, 272
 obsessive-compulsive disorder studies, 121
 panic disorder studies, 92
 personality disorder studies, 318
 post-traumatic stress disorder studies, 136
 schizophrenia studies, 235–237
 stimulant dependence studies, 307–308
 Tourette syndrome studies, 337
 mood disorders
 adoption studies, 4–5
 and anorexia nervosa, 263
 and bulimia nervosa, 263
 genetic epidemiology, 4
 heritability, 196
 mood stabilizers, pharmacogenetics, 59–61
 MOPr *see* mu-opioid receptor (MOPr)
 motif-based alignments, 42
 MRPL19, and reading disability, 163
 MSK1, 85
 MSP (multiple scan probability), 202
 MTC (methylthioninium chloride), 374
 MTHFR, and major depressive disorder, 216, 218–219
 multiple alignments, 42
 multiple comparisons, genetic variants, 19–20
 multiple scan probability (MSP), 202
 multi-threshold multifactorial model, 196–198
 multivariate genetic models, measured risk factors, 155–156
 mu-opioid receptor (MOPr)
 epigenetics, 298–299
 and opioid addiction, 297–298
 roles, 297
 MUSCLE, 42
 Mutation Discovery, 37–38
 mutations
 analysis tools, 37
 databases, 36–37, 39
 and non-uniform recombination rates, 19
 schizophrenia, 251
 MVP (mitral valve prolapse), 101
 MYOCD, and heroin addiction, 302–303

 nAChRs (nicotinic acetylcholine receptors), 290–291
NAPIL5, and obesity, 273, 275
 Naples high-excitability (NHE) rats, 178–179
 Naples low-excitability (NLE) rats, 178
 National Center for Biotechnology Information (NCBI), 39, 42, 44
 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 100–101
 Nazis, eugenics, 325–326
NCAM1, and alcoholism, 281–282
 NCBI Blast, 42
 NCBI (National Center for Biotechnology Information), 39, 42, 44
 NCBI VAST, 43
 Needleman–Wunsch algorithm, 42
 Neuregulin-1, 72–73
 neurochemical metabolites, as endophenotypes, 351–353
 neurocognitive deficits, anorexia nervosa, 263
 neurocognitive phenotypes, alcoholism, 353–359
 neurocognitive tests, attention-deficit hyperactivity disorder studies, 175
 neurodegenerative diseases, common themes in, 378
 neuroimaging, endophenotypes, 351
 neuroimaging studies
 attention-deficit hyperactivity disorder, 176
 panic disorder, 102–106
 neurons, olfactory, 71
 neuropeptide systems, genes involved in, 95
 neuropsychological deficits, schizophrenia, 234–235
 neuropsychopharmacology, field of study, 53
 neuroticism, 117
 neurotrophic model, of depression, 219
 next-generation sequencing, 23
 analysis, 30–31
 data analysis, 30–31
 data standards, 31
 emerging platforms, 29
 sequencing technologies, 31–32
 standards, 30–31
 technologies, 28–29
NFKB1, and alcoholism, 283
 NHE (Naples high-excitability) rats, 178–179
 nicotine dependence, 287–295
 and alcohol dependence, 294
 allele frequency distribution, 293
 comorbidities, 287–288, 294–295
 shared etiologies, 294
 definitions, 289
 and depression, 294
 diagnostic criteria, 288
 etiology, 287–288
 genetics, 288
 future research, 295
 genome-wide association studies, 289–290, 295
 limitations, 290
 heritability, 289
 prevalence, 287–288, 295
 and psychiatric disorders, genetics, 294–295
 stages, 288
 twin studies, 288
 nicotinic acetylcholine receptors (nAChRs), 290–291
 NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases), 100–101

Index

- NLE (Naples low-excitability)
 rats, 178
 noncoding RNA, Tourette syndrome
 studies, 343
 nonparametric linkage (NPL) method,
 122
 Tourette syndrome, 339
 nonpsychiatric disorders, and
 psychiatric disorders, 101–102
 nonrandom mating, 7
 nonsynonymous polymorphisms,
 39–40
 noradrenergic pathway, animal
 models, 177
 nortriptyline
 pharmacokinetics, 53–54
 studies, 55–56
 NOS1AP, and schizophrenia, 238–239
 NPAS3, and schizophrenia, 247
 NPL (non-parametric linkage)
 method, 122
 NPY
 and alcoholism, 282
 and cocaine administration, 83–84
 NRG1, and schizophrenia, 204, 243,
 252
 NTRK2
 and bipolar disorder, 203–204, 206
 and suicidal ideation, 56–57
 NTRK3, and major depressive
 disorder, 219
 obesity
 candidate genes, 273, 277
 copy number variations in, 273
 disparate approaches, 275
 epigenetic modifications, 275–276
 gene–environment interactions,
 272–273
 genetic expression differences, 276
 genetics, 272–277
 applications, 276
 future research, 276
 genome-wide association studies, 274
 heritability, 272
 linkage studies, 274
 parent of origin effects, 275
 polygenic model, 275
 prevalence, 272
 prevention, 276
 protective genes, 276
 rare genetic variants, 273
 resistance to, 276
 therapy, 276
 twin studies, 272
 obsessive–compulsive disorder (OCD)
 age of onset, as secondary
 phenotype in linkage
 studies, 122
 animal models, 128
 biological bases, 121
 candidate genes, 121, 123–126
 chromosomal anomalies, 130, 130
 chromosomal regions,
 candidate, 123
 and chromosome 22q deletion
 syndrome, 127–128
 and dystonia myoclonus
 syndrome, 127
 endophenotypes, 188
 environmental factors, 130
 family studies, 121, 123
 genes
 rare, 130
 SAPAP3, 128–130
 SLC1A1, 123–124, 130
 genetic epidemiology, 5
 genetics, 121–131
 formal, 122
 future research, 130–131
 genome-wide association studies,
 122–123, 130
 heterogeneity, 130
 linkage studies, 122
 onset, 121
 prevalence, 121
 and Tourette syndrome, 338
 twin studies, 121
 OCD *see* obsessive–compulsive
 disorder (OCD)
 odds ratios (ORs), 18
 in generalized anxiety disorder, 5
 in genome-wide association
 studies, 27
 offending, age of onset, 154
 6-OHDA (6-hydroxydopamine), 177
 olanzapine, 57–58, 276
 olfactory neurons, 71
 oligogenic modes, of inheritance, 6
 Online Mendelian Inheritance in Man
 (OMIM), 36–37
 opioid addiction
 and catechol-O-methyltransferase,
 300–301
 current research, 303
 gene association studies,
 hypothesis-driven, 302
 genetics, 297–303
 genome-wide association studies,
 302–303
 and 5-hydroxytryptamine-1B
 receptor, 301
 and kappa-opioid receptor, 299
 and melanocortin receptor type 2,
 299–300
 methadone treatment, 302
 and mu-opioid receptor,
 297–298
 risk factors, 297
 and tryptophan hydroxylase 1,
 301–302
 and tryptophan hydroxylase 2,
 301–302
 opioid system, and alcoholism, 282
 oppositional defiant disorder, 145
 heritability, 149
 prevalence, 149
 symptoms, 149
 twin studies, 149
 OPRD1
 and alcoholism, 282
 and eating disorders, 265
 OPRK1
 and alcoholism, 282
 and opioid addiction, 299
 OPRM1
 and alcoholism, 282
 and opioid addiction, 297–298
 ordered subset analysis
 (OSA), 188
 ORegAnno, 40–41
 ORs *see* odds ratios (ORs)
 OSA (ordered subset analysis), 188
 OSBPL1A, and bipolar disorder,
 206–207
 OXTR, and autism, 190
 P2RX7, and bipolar disorder, 204
 P50 suppression test, 350
 PAG *see* periaqueductal gray region
 (PAG)
 pairwise alignments, 42
 PALB2, and bipolar disorder, 205
 PANDAS (pediatric autoimmune
 neuropsychiatric disorders
 associated with streptococcal
 infections, 130
 panic attacks (PAs)
 induction, 96
 and panic disorder, 91
 panic disorder (PD), 90–107
 and agoraphobia, 118
 and brain abnormalities, 102
 case control studies, 98
 comorbidities, 90–92
 diagnosis, 90
 diagnostic criteria, 90
 variance, 92
 epidemiology, 90
 family studies, 90–92
 fear processing, 107
 functional imaging studies,
 102–104, 107
 future research, 107
 genes
 in adenosine system, 95
 in dopamine system, 94–95

- in GABA-ergic system, 95–96
- in G-protein signaling regulators, 95–96
- in neuropeptide systems, 95
- related to carbon dioxide hypersensitivity, 96
- in serotonin system, 93–94
- genetic epidemiology, 5, 90
- genetic studies, 90
 - conclusions, 96–97
 - issues, 107
 - limitations, 106
 - molecular, 92–97
- genome-wide association studies, 93, 106
- heritability, 92
- imaging genetics, 104–106
- linkage studies, 92, 99
- neuroimaging studies, 102–106
- and panic attacks, 91
- and phobias, 118–119
- prevalence, 90
- proband, 101
- and structural brain changes, 103
- structural imaging studies, 102
- symptoms, 90, 97
- twin studies, 90–92
- panic disorder syndrome
 - expanded spectrum approach, 97–102
 - study characteristics, 99
 - tests, 100
- panic phenotype, studies, 106–107
- papilin, encoding, 56–57
- PAPLN*, and suicidal ideation, 56–57
- parent of origin effects, in obesity, 275
- Paris Autism Research International Sibpair Study (PARIS), 183–186
- Parkinson's disease, databases, 37–38
- paroxetine
 - panic disorder studies, 93
 - pharmacokinetics, 53–54
- PAs *see* panic attacks (PAs)
- Pathguide, 45
- PathSys database, 46
- PATHWAY, 45
- pathway analysis, 44–46, 70
 - commercial tools, 46
 - future trends, 46
 - information sources, 44
- pathway data repositories, 45
- pathways
 - autism, 192–193
 - as networks, 45
 - pathway visualization, 45–46
- PATIKAwab, 46
- PCLO*, and major depressive disorder, 221
- PCL-R (Psychopathy Checklist-Revised), 150–151
- PCMI*, and schizophrenia, 243
- PD *see* panic disorder (PD)
- PDGene, 37–38
- PDYN*, and alcoholism, 282
- pediatric autoimmune neuropsychiatric disorders associated with streptococcal (PANDAS) infections, and obsessive-compulsive disorder, 130
- PENK*, and alcoholism, 282
- periaqueductal gray region (PAG), 102–103
- perinatal events, Tourette syndrome, 342
- Perlegen, 25
- personality
 - abnormal vs. normal compared, 316
 - epigenetics, 322
 - general dimensions, inheritance, 320–321
 - well-functioning, requirements, 317
- personality disorders
 - candidate genes, 321
 - common genetic factors, 319–320
 - definitional issues, 317
 - factor analysis, 320
 - genetics, 316–322
 - genome-wide association studies, 321–322
 - heritability, 319–321
 - inheritance, 318–320
 - multidimensional inventories, 320
 - quantitative multifactorial variability, 317–318
 - twin studies, 318, 320–321
 - see also* antisocial personality disorder
- personality traits, heritability, 326
- PET (positron emission tomography), 102
- Pfam, 43
- pharmacodynamics, 53–54
- pharmacogenetics
 - anticonvulsants, 59–61
 - antidepressants, 53–57
 - adverse reaction studies, 56
 - antipsychotic drugs, 57
 - adverse reaction studies, 58–59
 - attention-deficit hyperactivity disorder, 176
 - animal models, 179
 - of carbamazepine-induced Stevens-Johnson syndrome, 61
 - in clinical practice, 62
 - commercial tests, 65
 - conceptual issues, 61–65
 - definition, 53
 - lithium, 59–60
 - major depressive disorder, 53, 225
 - future trends, 227
 - mood stabilizers, 59–61
 - profiling, 65
 - in psychiatry, 53–65
 - schizophrenia, 251
 - see also* psychiatric pharmacogenetics
- pharmacokinetics
 - antidepressants
 - genetic effects on, 53–54
 - antipsychotic drugs, genetic factors, 57
 - definition, 53
- pharmacotherapy
 - applications, 57
 - psychiatric disorders, 53
 - and single nucleotide polymorphisms, 61–65
- phenotypes
 - concept of, 347
 - see also* endophenotypes
- phenotypic heterogeneity, 20
- phenytoin, 59
- phobias
 - and additive genes, 114–115, 117
 - classification, 112
 - comorbidities, 113
 - diagnosis, 112
 - epidemiology, 112–113
 - familial specificity, 114
 - familial transmission, 113
 - genetic epidemiology, 5, 113–118
 - future research, 119
 - genetics, 112–120
 - genomic studies, 118–119
 - heritability, sex differences, 114
 - and irrational fears, 113–115
 - meta-analyses, 103–104
 - and panic disorder, 118–119
 - prevalence, 112–113
 - twin studies, 114–115
 - variance, 116
 - see also* agoraphobia (AG), social phobia, specific phobia
- phobic disorders *see* phobias
- phonologic disorders, 160
- phosphoacetylation, 81
- phosphorylation, histones, 79–81
- PICALM*, and Alzheimer's disease, 375
- PKHD1*, and obesity, 276
- plasmids, transfection, 71
- Plato, *Republic*, 324–325
- pleiotropic models, 101
- pleiotropy, 6
- PLINK (software), 27

Index

- P-MATCH, 40
PMCH, and obesity, 276
PMut, 39–40
 polygenic model, obesity, 275
 polygenic modes, of inheritance, 6
 polymorphisms
 analysis tools, 37
 nonsynonymous, 39–40
 regulatory, 40–41
 see also copy number
 polymorphisms (CNPs); single
 nucleotide polymorphisms (SNPs)
 Polyphen, 39–40
POMC, and alcoholism, 282
 population attributable risk, 8
 population isolates, Tourette
 syndrome studies, 339–340
 population prevalence, 1–2
 population stratification, 308–309
 positron emission tomography
 (PET), 102
 postnatal brain maturation, 75
 post-traumatic stress disorder (PTSD),
 134–143
 adoption studies, 136
 animal models, 141
 comorbidities, genetic factors, 139,
 140
 conceptual development, 134–135
 diagnosis, 134
 epidemiology, 135
 diagnostic criteria, issues, 142
 and diathesis–stress model, 134
 epigenetics, 140–141
 family studies, 135–136
 and fear, 103–104
 future trends, 140–142
 and gene–environment
 interactions, 142
 genetic studies, 135–140
 candidate gene approach, 137,
 138
 case-control association, 137–140
 future trends, 142–143
 methodological issues, 142
 molecular, 137–140
 quantitative, 135–136
 genome-wide association studies,
 141–142
 historical background, 134–135
 prevalence, 135
 sex differences, 135
 trauma exposure, 135–137
 twin studies, 136, 140
PPP3C, and schizophrenia, 252
PPP3CC, and schizophrenia, 243
PPYRI, and obesity, 273
 Prader–Willi syndrome, 79–81, 275
 and autism compared, 365
 genetics, 365–366
 and genomic imprinting
 disorders, 365
 prevalence, 365
 predictive algorithms, 40
 PRINTS, 43
 privacy issues, genetic
 information, 329
PRNP, mutations, 378
PRODH, and schizophrenia,
 247–248
 prodynorphin gene, and stimulant
 dependence, 312
 PROSITE, 43
 protein chemistry, in genetic
 susceptibility factor studies,
 69–71
 protein kinases, 82
 protein phosphatases, 82
 proteins, 43
 overexpression, 71
 protein sequencing, 35
 protein structures, 43
PRPF31, and autism, 188–189
PSEN1
 and Alzheimer’s disease, 375
 and familial Alzheimer’s disease,
 371, 376
PSEN2
 and Alzheimer’s disease, 375
 and familial Alzheimer’s
 disease, 373
 pseudo single-molecule sequencing,
 concept of, 28
 PSI-MI, 45
 psychiatric disorders
 animal models, 73
 and antisocial behavior, 145
 biomarkers, identification, 49–50
 candidate gene association
 studies, 49
 classification
 endophenotypes, 9
 lack of validity, 6
 comorbidities, 7
 complexity in, sources of, 6
 and endophenotypes, 349
 family studies, 69
 gene expression studies, 49–51
 genetic bases, methods, 23
 genetic epidemiology of, 1–10
 genetic susceptibility factors for,
 functional validation, 69–77
 heritability estimates, 3
 impacts of genomics on, 9–10
 and nicotine dependence, genetics,
 294–295
 and non-psychiatric disorders,
 101–102
 pharmacotherapy, 53
 risk factors, 3
 risk ratios, 3
 transmission, complex patterns of, 6
 psychiatric genetics
 endophenotypes in, 347–360
 applications, 349–359
 future trends, 359–360
 identification criteria, 348–349
 psychiatric genetics research,
 computer-based analysis and
 resources, 34–47
 psychiatric pharmacogenetics
 field of study, 53
 future trends, 61–65
 implications for clinical practice,
 61–65
 psychiatric phenomics, field of
 study, 49
 psychiatric phenotypes,
 limitations, 49
 psychiatry
 epigenetic research, issues, 87
 pharmacogenetics in, 53–65
 psychic trauma, 134–135
 see also post-traumatic stress
 disorder (PTSD)
 psychopathy, 150–151
 and antisocial behavior, 145
 Psychopathy Checklist-Revised
 (PCL-R), 150–151
 psychopharmacology, limitations,
 61–65
 psychosocial stress, Tourette
 syndrome, 342
 psychostimulant dependence, 308–310
 psychostimulants
 use of term, 306
 see also stimulant dependence
 psychotic depression,
 pharmacotherapy, 57
 PTSD *see* post-traumatic stress
 disorder (PTSD)
 PubMed, 46
 punishment, and behavioral genetics,
 327–329
 PupaSuite, 36
p-values, 50–51
 QTL (quantitative trait loci), 275
 quantitative multifactorial variability,
 personality disorders, 317–318
 quantitative trait loci (QTL), 275
RAI1, and Smith–Magenis
 syndrome, 366
 rare genetic variants, 23
 autism, 191–192
 obesity, 273

- rare variant hypothesis, 191–192
 RAVEN (Regulatory Analysis of Variation in Enhancers), 40
 RCSB PDB, 43
 RD *see* reading disability (RD)
 Reactome, 45
 read depth (RD), 30–31
 reading disability (RD), 161–163
 comorbidities, 165
 deficits, 166
 future research, 166
 gene localizations, 161
 genetics, 161
 and language impairment
 compared, 164
 sex differences, 161
 read pairs (RPs), 30–31
 recombination, and linkages, 14–15
 recombination rates, non-uniform, and mutations, 19
 RefSeq, 45
 regulator of G-protein signaling (RGS), 96
 Regulatory Analysis of Variation in Enhancers (RAVEN), 40
 regulatory motifs, 41
 regulatory polymorphisms, 40–41
 regulatory RNAs, 51
 relative risk, 8
 RELN, and schizophrenia, 243, 252
 responsibility, and genetics, 326–329
 Rett's disorder, 364–365
 Rett syndrome, etiology, 82
 RGS4, and schizophrenia, 238–239
 RGS (regulator of G-protein signaling), 96
 risk alleles, 8
 risk estimation, 8
 risk factors
 antisocial behavior, 154–156
 see also measured risk factors
 risk ratios, psychiatric disorders, 3
 risperidone, 58
 RNA interference (RNAi), 71, 73–74
 RNA sequencing, analysis, 35
 ROBO1, and reading disability, 163
 Roche, 454 Sequencing System, 28–29
 Roche Diagnostic AmpliChip CYP450 test, 65
 rodents
 depression studies, 85
 drug-addiction studies, 83–85
 molecular manipulations, 73, 74
 see also mice
 RORA, and major depressive disorder, 225
 RPs (read pairs), 30–31
 SAD (social anxiety disorder), 100–101, 104
 sampling, family studies, 7
 SAM (sequence alignment/MAP), 31
 Sanger sequencing technology, 28–29
 SAPAP3, 128–130
 SBML, 45
 schizophrenia (SZ)
 adoption studies, 237
 and affective disorders, 233–234
 age of onset, 231–232
 anatomical and histological abnormalities, 76
 animal models, 73, 76
 anticipation and, 230–231
 association studies, 238
 and bipolar disorder, 230–231, 233–234, 208
 copy number variant differences, 250–251
 genetic association differences, 250–251
 candidate genes, 204, 231, 238–248
 animal and cell biology studies, 251–253
 functional polymorphisms and mutations, 251
 children, 4
 copy number variations, 249–250
 co-twin control studies, 235–237
 cytogenetic abnormalities, 249–250
 deletions, 249–250
 diagnostic criteria, 233–234
 diagnostic issues, 232
 duplications, 249–250
 endophenotypes
 eye-tracking dysfunction, 350
 neurocognitive, 350–351
 sensory motor gating, 350
 environmental risk factors, 4
 epigenetics, 231–232
 familial recurrence, 232–233
 familial transmission, 207
 family studies
 cognitive deficits and imaging changes, 234
 segregation analysis, 237–238
 variance component analysis, 237–238
 functional polymorphisms, 251
 future research, 46–47
 genetic epidemiology, 3–4
 genetic linkage, 238
 genetics, 230–253
 future research, 253
 genetic susceptibility factors, 4, 69
 heritability, 230–231
 and idiopathic generalized epilepsy, 249–250
 Kraepelinian type, 232–233
 linkage studies, 231
 loci, 239
 murine studies, 251–253
 neuropsychological deficits, with
 family genetic control, 234–235
 pharmacogenetics, 251
 pharmacotherapy, 57
 subtypes, family studies, 232–233
 twin studies, 235, 350–351
 segregation analysis, 237–238
 variance component analysis, 237–238
 SCOPE, 40
 second-generation sequencing
 see next-generation sequencing
 segregation analysis
 schizophrenia, 237–238
 Tourette syndrome, 337
 selection, artificial, 324
 selective serotonin reuptake inhibitors (SSRIs)
 adverse reaction studies, 56
 depression treatment, 85
 major depressive disorder
 treatment, 225
 panic disorder treatment, 93
 pharmacokinetics, 53–54
 SEMA5A, and autism, 187
 sensory motor gating, and
 schizophrenia, 350
 sequence alignment/MAP (SAM), 31
 sequence alignments, 41–43
 sequence analysis, 35
see also DNA sequencing
 sequence conservation, 41
 Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study, 55–56, 226
 treatment emergent suicidal ideation studies, 56–57
 sequence read format (SRF), 31
 sequencing, 28
 future research, 46–47
 see also DNA sequencing, next-generation sequencing
 Sequenom, 25
 serotonergic pathways, attention-deficit hyperactivity disorder, 172
 serotonergic system, 58, 105–106
 serotonin, in carbon dioxide hypersensitivity, 96
 serotonin norepinephrine reuptake inhibitors (SNRIs)
 adverse reaction studies, 56
 depression treatment, 85
 pharmacokinetics, 53–54
 serotonin receptor gene (*HTR2A*)
 see HTR2A

Index

- serotonin receptors, 107
 polymorphisms, 93–94
 serotonin receptor subunit genes, and
 antipsychotic drugs, 58
 serotonin system, genes involved in,
 93–94, 123–126
 serotonin transporter gene (*SLC6A4*)
 see SLC6A4
 serotonin-transporter-linked
 polymorphic region
 (5-HTTLPR), 54–55
 and adverse reactions, 56
 anorexia nervosa studies, 267
 bipolar disorder studies, 203
 major depressive disorder
 studies, 224
 obsessive–compulsive disorder
 studies, 123–126
 and personality disorders, 321
 polymorphisms, 93, 105–106
 post-traumatic stress disorder
 animal studies, 140
 studies, 140
 see also SLC6A4 SERT,
 organization, 125
 setshifting, and anorexia nervosa, 263
 sex differences
 animal phobias, 115
 antisocial personality disorder,
 317–318
 autism, 188, 191
 fragile X syndrome, 367
 major depressive disorder,
 215–216
 phobias
 heritability, 114
 prevalence, 113, 115
 post-traumatic stress disorder, 135
 reading disability, 161
 Tourette syndrome, 342
 shank3 point mutation, 192
 shell shock, 134–135
 see also post-traumatic stress
 disorder (PTSD)
 SHRs (spontaneously hypertensive
 rats), 178
 Sibling-pair designs, autism studies,
 183
 SIFT, 39–40
 simple phobia *see* specific phobia
 Single Nucleotide Polymorphism
 Database (dbSNP), 39
 single nucleotide
 polymorphism (SNP)
 genotyping, 23–28
 copy number analysis, 26
 family studies, 26–27
 genome-wide association studies,
 27–28
 linkage studies, 26–27
 see also high-density single
 nucleotide polymorphism (SNP)
 genotyping
 single nucleotide polymorphisms
 (SNPs), 13
 applications
 disease mapping, 23–24
 early, 24–25
 classic, 24
 classification, 24
 databases, 36–39
 definition, 23–24
 functional, 24
 linkage disequilibrium, 24
 mapping, 24
 nonfunctional, 24
 and pharmacotherapy, 61–65
 site-directed mutagenesis, 69–70
 SJS (Stevens–Johnson syndrome),
 carbamazepine-induced,
 pharmacogenetics, 61
 SLA6A2, animal models, 177
 SLC1A1
 in obsessive–compulsive disorder,
 123, 130
 studies, 124
 SLC1A3, in attention-deficit
 hyperactivity disorder,
 172–173
 and schizophrenia, 252
 SLC6A2
 and attention-deficit hyperactivity
 disorder, 172
 and major depressive disorder,
 55–56, 218–219
 and weight loss, 276
 SLC6A3, 137–139
 animal models, 176–178
 in attention-deficit hyperactivity
 disorder, 169, 173, 176
 and stimulant dependence, 310
 variants, 169–171, 175
 SLC6A4
 anorexia nervosa studies, 267–269
 and autism, 190
 bipolar disorder studies, 203
 major depressive disorder studies,
 218–219
 obsessive–compulsive disorder
 studies, 123–126
 panic disorder studies, 93
 pharmacogenetic studies, 54–55
 post-traumatic stress disorder
 studies, 140
 see also serotonin-transporter-
 linked polymorphic region
 (5-HTTLPR)
 SLI1 locus, 164, 166
 SLI2 locus, 164, 166
 SLI *see* specific language
 impairment (SLI)
 SLITRK1, and Tourette syndrome,
 336–337, 341
 Slit and Trk-like family member 1
 (*SLITRK1*) *see SLITRK1*
 Smith–Magenis syndrome
 (SMS), 366
 Smith–Waterman algorithm, 42
 smoking initiation, heritability, 288
 SMS *see* Smith–Magenis
 syndrome (SMS)
 SNAP-25, and attention-deficit
 hyperactivity disorder,
 172–173
 SNPEXpress, 44
 SNP genotyping *see* single nucleotide
 polymorphism (SNP)
 genotyping
 SNPs3D, 39–40
 SNPs *see* single nucleotide
 polymorphisms (SNPs)
 SNPs (single nucleotide
 polymorphisms), 13
 SNRIs *see* serotonin norepinephrine
 reuptake inhibitors (SNRIs)
 social anxiety disorder (SAD),
 100–101, 104
 social phobia
 and avoidant personality disorder
 compared, 117
 classification, 112
 diagnosis, 112
 familial transmission, 113
 genomic studies, 118
 prevalence, 112–113
 traits, family studies, 117–118
 see also generalized social
 phobia
 sodium butyrate, 224
 SP4, and major depressive
 disorder, 221
 spasmodic torticollis, 127
 SPCH1 locus, 164
 specific environment, use of
 term, 114
 specific language impairment (SLI),
 160
 specific phobia
 classification, 112
 diagnosis, 112
 familial transmission, 113
 genomic studies, 118
 prevalence, 112–113
 specific reading disability (SRD), 160
 speech sound disorder (SSD), 165–166
 definition, 160
 prevalence, 160

- spontaneously hypertensive rats (SHRs), 178
 SRD *see* specific reading disability (SRD)
 SRF (sequence read format), 31
 SSD *see* speech sound disorder (SSD)
 SSRIs *see* selective serotonin reuptake inhibitors (SSRIs)
 stable tubule-only polypeptide (STOP) proteins, and schizophrenia, 252
 STAR*D Study *see* Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study
 state-trait characteristics
 anorexia nervosa, 263–264
 bulimia nervosa, 263–264
 stem cells, 71
 see also induced pluripotent stem (iPS) cells
 STEP-BD (Systematic Treatment Enhancement Program for Bipolar Disorder), 205–206
 sterilization, 325
 Stevens–Johnson syndrome (SJS), carbamazepine-induced, pharmacogenetics, 61
 stimulant dependence
 candidate genes, 312
 and dopamine-related genes, 310–312
 family studies, 306–307
 future research, 314
 genetics, 306–314
 genome-wide association studies, 312–313
 heritability, 306–308
 markers, 309–310
 prevalence, 306
 twin studies, 306–307
 see also psychostimulant dependence
 STOP (stable tubule-only polypeptide) proteins, and schizophrenia, 252
 stratification, 20
 streptococcal infections, and obsessive–compulsive disorder, 130
 structural alignments, 43
 structural imaging studies, panic disorder, 102
 structural variants
 attention-deficit hyperactivity disorder, 173
 types of, 30–31
 STY13, and cocaine dependence, 313
 subPSEC, 39–40
 substance dependence, and antisocial behavior, 145
 substance use disorders, 148
 and antisocial behavior, 150
 family studies, 5, 6
 gene–environment interactions, 150
 genetic epidemiology, 5
 heritability, 150
 twin studies, 5–6
 suicidal behavior, and cortisol levels, 353
 suicidal ideation, 56–57
 Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), 205–206
 SZ *see* schizophrenia (SZ)
 TAAR6, and schizophrenia, 241–243
 TACR3, and alcoholism, 283
 TAMAL, 36
 tamoxifen, 276
 TaqI, 172
 tardive dyskinesia (TD), antipsychotic-induced, 58–59
 target enrichment, hybridization-based, 32
 TCAs *see* tricyclic antidepressants (TCAs)
 TCI (Temperament and Character Inventory), 320–321
 T-Coffee, 42
 TD *see* tardive dyskinesia (TD)
 TDTs *see* transmission disequilibrium tests (TDTs)
 Technical University of Denmark, Center for Biological Sequence Analysis, 43
 Temperament and Character Inventory (TCI), 320–321
 TEN (toxic epidermal necrolysis), carbamazepine-induced, 60–61
 TESIs (treatment emergent suicidal ideations), antidepressant-induced, 56–57
 testing
 for-profit, for genetic susceptibility, 331–332
 issues, addictions, 331
 in workplace, 333–334
 TF, and Alzheimer's disease, 376
 TH (tyrosine hydroxylase), 201–202, 204
 tics
 characterization, 336
 comorbidities, 337–338
 tobacco use
 prevalence, 287
 see also nicotine dependence
 Tourette syndrome (TS)
 and anxiety disorders, 338
 and attention-deficit hyperactivity disorder, 338
 candidate genes, 341
 comorbidities, 337–338
 copy number variations, 343
 cytogenetic abnormalities, 340–341
 and depression, 338
 environmental factors, 342
 epigenetics, 343–344
 family studies, 337
 genetics, 126–127, 336–344
 future research, 344
 future trends, 342–344
 genome-wide association studies, 342–343
 heritability, 337
 infection and immune response, 342
 linkage analysis, 338–339
 microarray studies, 342–343
 noncoding RNA studies, 343
 non-parametric linkage method, 339
 and obsessive–compulsive disorder, 338
 perinatal events, 342
 population isolates, 339–340
 prevalence, 337
 psychosocial stress, 342
 research, conclusions, 336
 segregation analysis, 337
 sex differences, 342
 studies, 336
 symptoms, 336
 twin studies, 337
 toxic epidermal necrolysis (TEN), carbamazepine-induced, 60–61
 TP1, 301–302
 TP2, 301–302
 TPH (tryptophan hydroxylase), 94
 TRα1, mutations, 178
 training data, 40
 traits, heritability, 113
 TRANSFAC database, 80
 transgenic animals, 178
 transgenic mice, 73
 Alzheimer's disease studies, 374
 translocations, 30–31
 transmission disequilibrium tests (TDTs), 18–19
 advantages, 27–28
 overview, 27–28
 tranylcypromine, 86, 224
 TRAR4, and schizophrenia, 241–243

Index

- trauma exposure
 assaultive versus non-assaultive, 136–137
 epidemiology, 135
 genetic factors, 136–137
 non-genetic factors, 137
 traumatic neurosis, 134–135
see also post-traumatic stress disorder (PTSD)
 treatment emergent suicidal ideations (TESIs), antidepressant-induced, 56–57
 trichotillomania, genetics, 128–130
 tricyclic antidepressants (TCAs), 53
 TRRD database, 40
 tryptophan hydroxylase 1 (*TPH1*)
 see TPH1
 tryptophan hydroxylase 2 (*TPH2*)
 see TPH2
 tryptophan hydroxylase (TPH), 94
 TS *see* Tourette syndrome (TS)
 TStag, 44
TTC12, and alcoholism, 281–282
 T variant, 15–17
 twin studies
 alcoholism, 279–280
 anorexia nervosa, 264–265
 antisocial behavior, 145–148, 156
 gene-environment interactions, 152
 antisocial personality disorder, 317
 attention-deficit hyperactivity disorder, 149–150, 168, 176
 autism, 183
 bipolar disorder, 196, 197
 bulimia nervosa, 264–265
 carbon dioxide hypersensitivity, 96
 conduct disorder, 149
 externalizing disorders, 116–117
 extraversion, 117
 generalized anxiety disorder, 119–120
 genetic epidemiology, 2
 heritability, 14
 internalizing disorders, 116–117
 major depressive disorder, 214–215, 224
 neuroticism, 117
 nicotine dependence, 288
 obesity, 272
 obsessive-compulsive disorder, 121
 oppositional defiant disorder, 149
 panic disorder, 90–92
 personality disorders, 318, 320–321
 phobias, 114–115
 environmental variance, 114
 genetic variance, 114
 prevalence, 113
 post-traumatic stress disorder, 136, 140
 psychopathy, 151
 schizophrenia, 235, 350–351
 segregation analysis, 237–238
 variance component analysis, 237–238
 stimulant dependence, 306–307
 substance use disorders, 5–6
 Tourette syndrome, 337
 see also dizygotic (DZ) twins, monozygotic (MZ) twins
 tyrosine hydroxylase (TH), 201–202, 204

UBE3A, and Angelman syndrome, 365
UBE3C, and major depressive disorder, 225
UCP1, and obesity, 273
 UCSC Genome Browser, 40–41
UHMKI, and schizophrenia, 238–239
 unconditioned fear, 102–103
 unipolar depression *see* major depressive disorder (MDD)
U.S., v. Durham, 327–328

Val66Met, polymorphisms, 140
val158met, polymorphisms, 105
 valproate, 59, 224
 valproic acid, 299
 Val/Val genotype, 172
 variable expressivity, 6
 variable number tandem repeats (VNTRs), 94, 203
 variance component analysis, schizophrenia, 237–238
 variant consensus format (VCF), 31
 variant identification
 in human genome, 13
 strategies, 34
 variant segregation, and linkage disequilibrium, 15–17
 VBRs (ventricle-brain ratios), 234
 VCFS *see* velo-cardio-facial syndrome (VCFS)

 VCF (variant consensus format), 31
 velo-cardio-facial syndrome (VCFS), 4, 249–250
 genetics, 127–128, 247–248
 venlafaxine, pharmacokinetics, 53–54
 ventricle-brain ratios (VBRs), 234
 vesicular neurotransmission, regulatory mechanisms, 172–173
 violence, 145
 genetic factors, 328–329
 viral vectors, infection, 71
 VisANT, 46
 VISTA Enhancer Browser, 40–41
 VMP, and reading disability, 163
 VNTRs (variable number tandem repeats), 94, 203

 warfarin, pharmacogenetic profiling, 65
 war neurosis, 134–135
 see also post-traumatic stress disorder (PTSD)
WDR59, and bipolar disorder, 206–207
 WebLogo, 41
 weight gain
 antipsychotic-induced, 58–59
 drug-induced, 276
 weight loss, genetics, 276
 Weka, 40
WGAS see genome-wide association (GWA) studies
 WGA studies *see* genome-wide association (GWA) studies
 Wistar Kyoto (WKY) strain, 178
 word methods, 42
 workplace, testing in, 333–334
 WorldWide Protein Data Bank, 43

 X-inactivation, 79–81

 yeast two-hybrid assays, 69–71

 zebrafish, as animal models, 73
 zinc finger proteins, 87–88
ZNF804A, and schizophrenia, 239–240